PFIZER INC reported adjusted first-quarter profit of 75 cents per share, beating analyst estimates of 72 cents. The result was driven by sustained demand for established products like the blood thinner Eliquis. Strong performance in legacy drugs provides a buffer as the drugmaker navigates post-pandemic revenue shifts.

Legacy Portfolio Drives Earnings Beat